Findings from several studies presented at ESC Heart Failure Congress 2026 in Barcelona, Spain, were simultaneously published in JACC and JACC: Heart Failure, covering topics like arrhythmic burden in cardiac amyloidosis (CA), stroke and bleeding risk in CA, and survival among patients undergoing left ventricular assist device (LVAD) implantation vs. heart transplantation.
In the prospective EXCALIBUR study, seeking to characterize arrhythmic burden among patients with differing subtypes of CA, Adam Ioannou, MBBS, et al., found that clinically significant arrythmias were common and often asymptomatic.
In total, 110 patients with a new diagnosis of either transthyretin amyloid cardiomyopathy (ATTR-CM) or light-chain CA (AL-CA) were included. They underwent comprehensive phenotyping with cardiac magnetic resonance and then received an implantable loop recorder.